NYSE:ELANElanco Animal Health Stock Price, Forecast & News

Elanco Animal Health's stock was trading at $23.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ELAN stock has increased by 2.4% and is now trading at $24.30.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Elanco Animal Health.

Elanco Animal Health is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Elanco Animal Health.

Elanco Animal Health (NYSE:ELAN) released its quarterly earnings data on Thursday, July, 30th. The company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.07. The firm had revenue of $586.30 million for the quarter, compared to the consensus estimate of $555.84 million. Elanco Animal Health had a negative net margin of 3.63% and a positive return on equity of 4.68%.
View Elanco Animal Health's earnings history.

Elanco Animal Health issued an update on its third quarter 2020 Pre-Market earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $660-710 million, compared to the consensus revenue estimate of $785.5 million.

10 brokerages have issued 12 month target prices for Elanco Animal Health's shares. Their forecasts range from $19.00 to $32.00. On average, they expect Elanco Animal Health's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Elanco Animal Health.

Headlines about ELAN stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Elanco Animal Health earned a news sentiment score of -4.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Elanco Animal Health.

Some companies that are related to Elanco Animal Health include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT) and Teva Pharmaceutical Industries (TEVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Walt Disney (DIS), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Home Depot (HD) and Pfizer (PFE).

(ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Elanco Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (2.77%), Vantage Investment Partners LLC (0.79%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Swiss National Bank (0.40%), Academy Capital Management Inc. TX (0.27%) and Douglas Lane & Associates LLC (0.23%). Company insiders that own Elanco Animal Health stock include Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young.
View institutional ownership trends for Elanco Animal Health.

ELAN stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Wafra Inc., DekaBank Deutsche Girozentrale, Three Peaks Capital Management LLC, Arizona State Retirement System, New York State Common Retirement Fund, Raymond James & Associates, and WINTON GROUP Ltd.
View insider buying and selling activity for Elanco Animal Health.

ELAN stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Academy Capital Management Inc. TX, Public Employees Retirement Association of Colorado, Douglas Lane & Associates LLC, Janney Capital Management LLC, Envestnet Asset Management Inc., Sanders Morris Harris LLC, and Sciencast Management LP. Company insiders that have bought Elanco Animal Health stock in the last two years include Art A Garcia, David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral, and Todd S Young.
View insider buying and selling activity for Elanco Animal Health.

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ELAN stock can currently be purchased for approximately $24.30.

Elanco Animal Health has a market capitalization of $9.69 billion and generates $3.07 billion in revenue each year. The company earns $67.90 million in net income (profit) each year or $1.06 on an earnings per share basis. Elanco Animal Health employs 6,080 workers across the globe.

The official website for Elanco Animal Health is www.elanco.com.

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.